氯倍他索

Clobetasol

未知生产厂商

Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

技术标识符

化学式: C₂₂H₂₈ClFO₄
CAS 编号: 25122-41-2
UNII ID: ADN79D536H

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
- US 8709469 B2
  申请人: DUGAN STEPHEN优先权: 2010
  US
  5 件公开
- US 7758881 B2
  申请人: ADVANCED CARDIOVASCULAR SYSTEM优先权: 2005
  US
  2 件公开
- US 8435550 B2
  申请人: CHENG JIN优先权: 2008
  US
  2 件公开
Ointment for combating and treating skin diseases, and process for preparing said ointment
EP 2025341 A1申请人: RAMOS PRIETO JOSE优先权: 2007
CN
EP
US
3 件公开
METHOD OF TREATING OPERATIVE COMPLICATIONS OF CATARACT SURGERY
EP 4704853 A1申请人: FORMOSA PHARMACEUTICALS INC优先权: 2023
CN
EP
WO
3 件公开
CORTICOSTEROID NANOSUSPENSIONS AND USES THEREOF
EP 4704852 A2申请人: AIMMAX THERAPEUTICS INC优先权: 2023
CN
EP
WO
3 件公开
Stabilized composition for treating psoriasis
US 9220701 B2申请人: WEI WILLIAM SHIFENG优先权: 2009
CN
US
3 件公开
Transdermal drug delivery system and method of using the same
US 8900626 B2申请人: OGAWA TAKAHIRO优先权: 2011
CN
US
3 件公开
Patch for treatment of eyelid disease containing clobetasol
US 9211397 B2申请人: SENJU USA INC优先权: 2012
CN
US
3 件公开
Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US 2006002968 A1申请人: STEWART GORDON优先权: 2004
US
3 件公开
Calcitriol/clobetasol propionate compositions for the treatment of psoriasis
US 2005282792 A1申请人: GALDERMA SA优先权: 2004
CN
US
2 件公开
Cosmetic/dermatological inverse emulsions containing calcitriol and clobetasol 17-propionate
US 2005281850 A1申请人: GALDERMA SA优先权: 2004
CN
US
2 件公开

药物

氯倍他索

概览

专利

Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device